Status:
COMPLETED
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This single arm study evaluated the efficacy and safety of first-line chemotherapy with carboplatin and dose-dense weekly paclitaxel plus bevacizumab (Avastin) in participants with epithelial ovarian,...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Female patients, ≥ 18 years of age.
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Initial surgery, but no chemotherapy or radiotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Exclusion Criteria
- Non-epithelial tumors.
- Ovarian tumors with low malignant potential.
- Previous systemic anti-cancer therapy for ovarian cancer.
- History or evidence of synchronous primary endometrial cancer.
- Current or recent daily treatment with aspirin (\> 325mg/day) or with full dose anticoagulant or thrombolytic agents for therapeutic purposes.
Exclusion
Key Trial Info
Start Date :
June 25 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT00937560
Start Date
June 25 2009
End Date
July 1 2013
Last Update
November 6 2017
Active Locations (55)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Amaral Carvalho
Jaú, São Paulo, Brazil, 17210-080
2
Hospital das Clinicas - FMUSP, Oncologia
São Paulo, São Paulo, Brazil, 05403-000
3
Centre Hospitalier Henri Duffaut; Hematologie
Avignon, France, 84902
4
Clinique Tivoli; Sce Radiotherapie
Bordeaux, France, 33000